Geron Corporation (GERN NASDAQ) stock market data APIs
$1.2784
0.04(3.1%)
as of September 12, 2025
Try our APIs with
free plan!
Geron Corporation Financial Data Overview
Price chart is built with
Anychart
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Prev. Close
1.2784
Open
1.3186
High
1.3252
Low
1.2784
52 wk Range
1.09-4.825
Market Cap
810 M
Shares Outstanding
638 M
Revenue
164 M
EPS
-0.02
Beta
0.634
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Geron Corporation (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Geron Corporation data using free add-ons & libraries
Get Geron Corporation Fundamental Data
Geron Corporation Fundamental data includes:
- Net Revenue: 164 M
- EBITDA: -76 991 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Geron Corporation News
New
Next Generation Drug Conjugates Market Report 2025-2035, with Profiles of Advanced Accelerator Applications, Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Geron, & Ionis Pharmaceuticals
Company Logo The next generation drug conjugates market offers significant growth potential driven by their targeted therapeutic capabilities for diseases like cancer and hemophilia. Key opportunitie...
Needham Keeps Buy Rating on Geron (GERN) After Q2 Results
Geron Corporation (NASDAQ:GERN) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 6, Needham reiterated its Buy rating for Geron Corporation (NASDAQ:GERN) with a price target o...
SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Bo...
SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors
SpyGlass Pharma, Inc. ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
